IASLC World Conference on Lung Cancer

Tarlatamab Combined with Anti-PD-L1 Shows Promising Safety and Unprecedented Overall Survival as First-Line Maintenance Therapy Following Chemo-Immunotherapy in ES-SCLC

September 8, 2025

In a significant advancement within the landscape of lung cancer therapeutics, novel clinical data unveiled at the 2025 International Association ...

UK Study Finds Lung Cancer Screening Benefits Adults Up to Age 80 Who Are Surgical Candidates

by SCIENMAG

September 8, 2025

(Barcelona, Spain, September 8, 2025, 10:45 a.m. CEST / UTC +2) — Recent findings presented at the prestigious International Association ...

EA5181 Phase 3 Trial Shows No Overall Survival Advantage for Concurrent Plus Consolidative Durvalumab Over Consolidation Alone in Unresectable Stage 3 NSCLC

by SCIENMAG

September 8, 2025

(Barcelona, Spain – September 8, 2025, 10:45 a.m. CEST / UTC +2) — In a pivotal development presented at the ...

Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment

by SCIENMAG

September 7, 2025

In a groundbreaking advancement for the management of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...

COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC

by SCIENMAG

September 6, 2025

In a groundbreaking development in the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...

Tag: IASLC World Conference on Lung Cancer

Tarlatamab Combined with Anti-PD-L1 Shows Promising Safety and Unprecedented Overall Survival as First-Line Maintenance Therapy Following Chemo-Immunotherapy in ES-SCLC

UK Study Finds Lung Cancer Screening Benefits Adults Up to Age 80 Who Are Surgical Candidates

EA5181 Phase 3 Trial Shows No Overall Survival Advantage for Concurrent Plus Consolidative Durvalumab Over Consolidation Alone in Unresectable Stage 3 NSCLC

Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment

COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC

Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

Bee body mass, pathogens and local climate influence heat tolerance

Researchers record first-ever images and data of a shark experiencing a boat strike

Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function

RECENT NEWS

Categories

Subscribe to Blog via Email

Welcome Back!

Retrieve your password